Crystal structure of phenylmethanesulfonyl fluoride-treated human chymase at 1.9 A.McGrath, M.E., Mirzadegan, T., Schmidt, B.F.
(1997) Biochemistry 36: 14318-14324
- PubMed: 9400368
- DOI: 10.1021/bi971403n
- PubMed Abstract:
- Production of Crystallizable Human Chymase from a Bacillus Subtilis System
Mcgrath, M.E.,Osawa, A.E.,Barnes, M.G.,Clark, J.M.,Mortara, K.D.,Schmidt, B.F.
(1997) FEBS Lett. 413: 486
The X-ray crystal structure of human chymase has been determined to 1.9 A resolution using molecular replacement methods. This first structure of human chymase is present as the Ser 195 ester of alpha-toluenesulfonic acid. The refined structure (Rcry ...
The X-ray crystal structure of human chymase has been determined to 1.9 A resolution using molecular replacement methods. This first structure of human chymase is present as the Ser 195 ester of alpha-toluenesulfonic acid. The refined structure (Rcryst = 0.183) shows that the inhibitor phenyl moiety lies at the top of the major specificity pocket, S1, while the sulfur is covalently linked to Ser 195-O gamma. The sulfonyl oxygens interact with the oxyanion hole and with His 57-N delta 1. The presence of the inhibitor disturbs the usual gauche position of His 57 and forces it to the trans conformer. Though the primary binding pockets are similarly specific in chymase and chymotrypsin, examination of the extended substrate binding sites reveals the structural basis for chymase's greater discrimination in choosing substrates. The larger 30s loop and its proximity to the active site indicates that it contacts substrate residues C-terminal to the scissile bond. Modeling of substrate at the chymase active site suggests that binding energy may be gained by three main-chain hydrogen bonds provided by substrate residues P2' and P4' and that discriminating interactions with substrate side chains are also likely. The presence of Lys 40 in S1' of human chymase explains its preference for Asp/Glu at P1'. Moreover, the cationic nature of S1' provides a structural basis for human chymase's poor catalytic efficiency when angiotensin II is the substrate.
Arris Pharmaceutical, South San Francisco, California 94080, USA. email@example.com